DDInter1024 DDInter604
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Medrysone
Medrysone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Testosterone Propionate
Testosterone Propionate {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Drospirenone
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Drospirenone (Compound)
Lapatinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Medrysone (Compound) and Medrysone (Compound) resembles Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Lapatinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Lapatinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Testosterone Propionate (Compound) and Testosterone Propionate (Compound) resembles Drospirenone (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Drospirenone (Compound)